CSPC.Y Stock Overview
An investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People’s Republic of China, other Asian regions, North America, Europe, and internationally. More details
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 1/6 |
Past Performance | 2/6 |
Financial Health | 5/6 |
Dividends | 4/6 |
CSPC Pharmaceutical Group Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | HK$2.57 |
52 Week High | HK$3.82 |
52 Week Low | HK$2.25 |
Beta | 0.64 |
11 Month Change | -18.03% |
3 Month Change | 6.81% |
1 Year Change | -24.96% |
33 Year Change | -37.98% |
5 Year Change | -53.38% |
Change since IPO | -13.60% |
Recent News & Updates
Recent updates
Shareholder Returns
CSPC.Y | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | -2.5% | 2.8% | 2.2% |
1Y | -25.0% | 11.8% | 32.6% |
Return vs Industry: CSPC.Y underperformed the US Pharmaceuticals industry which returned 9.9% over the past year.
Return vs Market: CSPC.Y underperformed the US Market which returned 31.6% over the past year.
Price Volatility
CSPC.Y volatility | |
---|---|
CSPC.Y Average Weekly Movement | 8.2% |
Pharmaceuticals Industry Average Movement | 9.5% |
Market Average Movement | 6.3% |
10% most volatile stocks in US Market | 15.8% |
10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CSPC.Y has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: CSPC.Y's weekly volatility (8%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1992 | 20,300 | Cuilong Zhang | www.cspc.com.hk |
CSPC Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People’s Republic of China, other Asian regions, North America, Europe, and internationally. The company operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. It provides NBP soft capsules and injections for acute ischemic stroke; Oulaining capsules and injections to treat mild to moderate memory and mental impairment; Enxi to treat adult idiopathic Parkinson’s disease; Duomeisu for lymphoma, multiple myeloma, ovarian and breast cancers, and other malignant tumors; Jinyouli to prevent leucopenia and infection induced by chemotherapy; and Keaili for breast cancer.
CSPC Pharmaceutical Group Limited Fundamentals Summary
CSPC.Y fundamental statistics | |
---|---|
Market cap | US$7.59b |
Earnings (TTM) | US$712.30m |
Revenue (TTM) | US$4.18b |
10.7x
P/E Ratio1.8x
P/S RatioIs CSPC.Y overvalued?
See Fair Value and valuation analysisEarnings & Revenue
CSPC.Y income statement (TTM) | |
---|---|
Revenue | CN¥30.27b |
Cost of Revenue | CN¥8.90b |
Gross Profit | CN¥21.37b |
Other Expenses | CN¥16.21b |
Earnings | CN¥5.16b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 0.44 |
Gross Margin | 70.59% |
Net Profit Margin | 17.04% |
Debt/Equity Ratio | 1.1% |
How did CSPC.Y perform over the long term?
See historical performance and comparisonDividends
6.3%
Current Dividend Yield61%
Payout RatioDoes CSPC.Y pay a reliable dividends?
See CSPC.Y dividend history and benchmarksCSPC Pharmaceutical Group dividend dates | |
---|---|
Ex Dividend Date | Nov 01 2024 |
Dividend Pay Date | Dec 05 2024 |
Days until Ex dividend | 26 days |
Days until Dividend pay date | 8 days |
Does CSPC.Y pay a reliable dividends?
See CSPC.Y dividend history and benchmarks